Hikma Gains FDA Approval for Novel TYZAVAN™, a Ready-to-Use Vancomycin Injection
Hikma Pharmaceuticals PLC has received approval from the U.S. Food and Drug Administration (FDA) for TYZAVAN™ (Vancomycin Injection, USP), a novel, ready-to-infuse form of the widely used antibiotic vancomycin.
This marks a major advancement in streamlining antibiotic therapy in hospitals and other clinical environments.
TYZAVAN™ is designed for use in both adult and pediatric patients (aged one month and older) and is approved for treating several serious bacterial infections.
These include septicemia, infective endocarditis, skin and soft tissue infections, osteomyelitis, and lower respiratory tract infections.
Unlike traditional vancomycin formulations, TYZAVAN™ is supplied in pre-filled, ready-to-infuse IV bags that do not require reconstitution, thawing, or dilution.
This innovation simplifies preparation and accelerates treatment, reducing strain on pharmacy and nursing staff.
A key feature of TYZAVAN™ is its room temperature stability—it is currently the only FDA-approved vancomycin injection that can be stored without refrigeration for up to 16 months.
The product is available in seven strengths, ranging from 0.5g to 2g, allowing for both fixed and weight-based dosing. Its compatibility with automated dispensing cabinets further supports efficient integration into hospital workflows.
The urgent nature of conditions like sepsis, which is diagnosed every 20 seconds and contributes to a death approximately every two minutes in the U.S., the availability of a ready-to-administer antibiotic formulation like TYZAVAN™ could enhance timely, life-saving interventions.
